Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Jeffrey Chodakewitz sold 3,437 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $151.64, for a total transaction of $521,186.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Jeffrey Chodakewitz also recently made the following trade(s):

  • On Wednesday, August 2nd, Jeffrey Chodakewitz sold 1,796 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $154.13, for a total transaction of $276,817.48.
  • On Thursday, August 3rd, Jeffrey Chodakewitz sold 5,390 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $154.17, for a total transaction of $830,976.30.
  • On Friday, July 21st, Jeffrey Chodakewitz sold 46,733 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $160.96, for a total transaction of $7,522,143.68.
  • On Monday, July 17th, Jeffrey Chodakewitz sold 573 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $129.85, for a total transaction of $74,404.05.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) remained flat at $152.51 during mid-day trading on Wednesday. 970,185 shares of the stock traded hands. The company has a market capitalization of $38.45 billion, a PE ratio of 146.50 and a beta of 1.73. Vertex Pharmaceuticals Incorporated has a one year low of $71.46 and a one year high of $167.85. The company has a 50-day moving average of $153.75 and a 200 day moving average of $132.80.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.33. The company had revenue of $544.10 million for the quarter, compared to analysts’ expectations of $489.95 million. Vertex Pharmaceuticals had a net margin of 12.05% and a return on equity of 4.64%. The business’s revenue was up 26.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.24 EPS. Equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post $1.62 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Vertex Pharmaceuticals Incorporated (VRTX) CMO Jeffrey Chodakewitz Sells 3,437 Shares” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/10/04/vertex-pharmaceuticals-incorporated-vrtx-cmo-jeffrey-chodakewitz-sells-3437-shares.html.

A number of research firms have commented on VRTX. DA Davidson began coverage on shares of Vertex Pharmaceuticals in a research note on Friday, September 29th. They issued a “buy” rating and a $200.00 price objective on the stock. BTIG Research began coverage on shares of Vertex Pharmaceuticals in a research note on Friday, September 29th. They issued a “buy” rating and a $200.00 price objective on the stock. BMO Capital Markets restated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, September 27th. Zacks Investment Research upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $174.00 price objective on the stock in a research note on Tuesday, September 26th. Finally, Vetr lowered shares of Vertex Pharmaceuticals to a “sell” rating in a research note on Thursday, September 21st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, twenty-three have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $167.04.

Several institutional investors and hedge funds have recently made changes to their positions in VRTX. Guardian Life Insurance Co. of America grew its stake in shares of Vertex Pharmaceuticals by 0.6% in the 1st quarter. Guardian Life Insurance Co. of America now owns 956 shares of the pharmaceutical company’s stock worth $105,000 after purchasing an additional 6 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in shares of Vertex Pharmaceuticals by 15.4% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock worth $127,000 after purchasing an additional 132 shares during the last quarter. FNY Partners Fund LP grew its stake in shares of Vertex Pharmaceuticals by 900.0% in the 2nd quarter. FNY Partners Fund LP now owns 1,000 shares of the pharmaceutical company’s stock worth $128,000 after purchasing an additional 900 shares during the last quarter. Dupont Capital Management Corp acquired a new position in shares of Vertex Pharmaceuticals in the 2nd quarter worth approximately $186,000. Finally, State of Alaska Department of Revenue acquired a new position in shares of Vertex Pharmaceuticals in the 2nd quarter worth approximately $197,000. 92.85% of the stock is currently owned by institutional investors.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.